Shin Nippon Biomedical Laboratories, Ltd.
Fiscal Year Ending March 2026 Q3 Financial Results Presentation Materials
Cumulative Q3 sales for FY2026 were 21.19 billion yen, a 4.7% decrease YoY, with operating income of 1.02 billion yen, down 46.1% YoY. The full-year earnings forecast was revised downward, projecting sales of 30.69 billion yen and operating income of 2.60 billion yen.
Key Figures
- Cumulative Q3 Sales: 21.19 billion yen (4.7% decrease YoY)
- Cumulative Q3 Operating Income: 1.02 billion yen (46.1% decrease YoY)
- Full-Year Sales Forecast: 30.69 billion yen (7.7% decrease from initial forecast)
AI要約
Performance Overview
Cumulative sales for the third quarter of FY ending March 2026 amounted to 21.19 billion yen, a 4.7% decrease YoY, with operating income at 1.02 billion yen, down 46.1% YoY. The primary reasons were a delay in sales recognition for large studies in the Nonclinical CRO business to the fourth quarter and increased operating losses due to a 560 million yen expense booked by Satsuma Co. Increased depreciation from capital investments also pressured profits. However, orders from European and American customers in the Nonclinical CRO business remained solid, with Q3 order intake reaching 10.0 billion yen, a record high with a 13.7% YoY increase.
Full-Year Outlook and Future Direction
The full-year earnings forecast was revised downward to sales of 30.69 billion yen, operating income of 2.60 billion yen, ordinary income of 5.35 billion yen, and net income attributable to owners of the parent of 3.56 billion yen. The main factors were the second half expense recognition of 1.24 billion yen for Satsuma Co. and a shift in sales recognition timing in the Nonclinical CRO business. Conversely, the TR business is expected to contain operating profit downward revisions through expense control. The Nonclinical CRO business has also signed new preferred contracts with major pharmaceutical companies domestically and abroad, continuing efforts to secure contracts in Q4.
